Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
🌎 Global
Global
United States
Australia
United Kingdom
Canada
India
China
Argentina
Austria
Bahrain
Bangladesh
Belgium
Bermuda
Botswana
Brazil
Bulgaria
Chile
Colombia
Croatia
Cyprus
Czech Republic
Denmark
Egypt
Estonia
Finland
France
Germany
Ghana
Greece
Hong Kong
Hungary
Iceland
Indonesia
Ireland
Israel
Italy
Ivory Coast
Jamaica
Japan
Jordan
Kenya
Kuwait
Latvia
Lithuania
Luxembourg
Malawi
Malaysia
Malta
Mauritius
Mexico
Morocco
Namibia
Netherlands
New Zealand
Nigeria
Norway
Oman
Pakistan
Palestinian Authority
Peru
Philippines
Poland
Portugal
Qatar
Romania
Russia
Saudi Arabia
Serbia
Singapore
Slovakia
Slovenia
South Africa
South Korea
Spain
Sri Lanka
Sweden
Switzerland
Taiwan
Tanzania
Thailand
Trinidad & Tobago
Tunisia
Turkey
Uganda
Ukraine
United Arab Emirates
Venezuela
Vietnam
Zambia
Zimbabwe
Create a narrative
Global Community
Our community narratives are driven by numbers and valuation.
Create a narrative
Community Investing Ideas
Global Weekly Picks
Airbnb
TI
TickerTickle
Community Contributor
Airbnb (ABNB): Still one of the most interesting bets in travel
Key insights Airbnb is changing from a travel-only app to a full lifestyle platform (stays, rentals, experiences) International markets are growing faster than the US, which is slowing down Product experience is improving a lot, with AI making search and booking easier Regulations are becoming a big risk, especially in Europe where listings are getting removed The way people move around the world has changed. It’s not only about holidays anymore.
View narrative
US$163.75
FV
23.6% undervalued
intrinsic discount
12.00%
Revenue growth p.a.
Set Fair Value
12
users have liked this narrative
7
users have commented on this narrative
49
users have followed this narrative
New
narrative
ING Groep
PI
PittTheYounger
Community Contributor
ING leads the pack when it comes to pivoting towards non-lending income
ING, of course, is a bank; and banks don't like falling interest rates, right? For the dominant stream of income is their core business model, i.e. borrowing short-term and lending long-term, reaping the difference in interest rates in the process.
View narrative
€27.92
FV
23.7% undervalued
intrinsic discount
9.00%
Revenue growth p.a.
Set Fair Value
7
users have liked this narrative
0
users have commented on this narrative
17
users have followed this narrative
New
narrative
Coles Group
RO
Robbo
Community Contributor
Coles (ASX: COL): Safe, Steady, and Surprisingly Cheap
The supermarket chain Coles is the kind of “boring” business that may have been overlooked as an investment opportunity. Although it was divested from Wesfarmers in 2018, Coles’ heritage traces back to 1914 — giving it over 110 years of history.
View narrative
AU$22.00
FV
4.0% undervalued
intrinsic discount
8.72%
Revenue growth p.a.
Set Fair Value
6
users have liked this narrative
2
users have commented on this narrative
17
users have followed this narrative
New
narrative
All companies
Popular
Undervalued
Overvalued
Load previous narratives
CommScope Holding Company
AN
AnalystHighTarget
Consensus Narrative from 4 Analysts
5G, Smart Cities And IoT Will Unlock Connectivity Potential
Key Takeaways Sharpened focus on high-growth networking and leaner operations positions the company for sustained margin gains and recurring revenue acceleration. Strategic divestiture and enhanced partnerships enable outsized contract wins, earnings uplift, and resilient long-term market share expansion.
View narrative
US$20.00
FV
22.5% undervalued
intrinsic discount
12.40%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
1
users have followed this narrative
2 days ago
author updated this narrative
CareDx
AN
AnalystHighTarget
Consensus Narrative from 5 Analysts
AlloSure And AlloMap Will Boost Molecular Transplant Care Despite Hurdles
Key Takeaways Breakthroughs in AI-driven diagnostics, digital health expansion, and strong clinical validation position CareDx for outsized revenue growth and margin acceleration beyond current forecasts. Advanced digitization and integration with major healthcare platforms streamline operations, enhancing net margins, cash flow, and creating sticky, high-margin recurring revenue streams.
View narrative
US$28.00
FV
57.7% undervalued
intrinsic discount
16.34%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
2 days ago
author updated this narrative
Maravai LifeSciences Holdings
AN
AnalystHighTarget
Consensus Narrative from 8 Analysts
mRNA And Cell Therapy Demand Will Transform Global Markets
Key Takeaways Aggressive cost reductions and organizational streamlining are poised to significantly boost operating leverage, driving margin expansion and rapid earnings recovery. Maravai's leadership in innovation, global expansion, and specialized biotech solutions positions it for sustained top-line outperformance and resilient, long-term revenue growth.
View narrative
US$5.00
FV
47.8% undervalued
intrinsic discount
4.18%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
2 days ago
author updated this narrative
Alpha and Omega Semiconductor
AN
AnalystHighTarget
Consensus Narrative from 3 Analysts
Electrification, Renewables And IoT Will Drive Enduring Market Leadership
Key Takeaways Rapid AI, graphics, and e-mobility adoption positions the company for significant growth, margin expansion, and deeper integration across hyperscale, consumer, and automotive markets. Enhanced financial strength enables aggressive investment in innovation and manufacturing, boosting competitiveness in high-value segments like renewables and industrial automation.
View narrative
US$35.00
FV
24.3% undervalued
intrinsic discount
6.72%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
2 days ago
author updated this narrative
Arvinas
AN
AnalystHighTarget
Consensus Narrative from 18 Analysts
Precision Medicine Trends Will Expand PROTAC Applications Despite Risks
Key Takeaways Regaining global rights and leveraging AI-driven PROTAC design could unlock significant revenue, pipeline productivity, and long-term earnings power through licensing or strategic transactions. Pipeline breakthroughs and industry shifts toward targeted protein degradation position Arvinas for rapid market expansion, revenue diversification, and enhanced valuation.
View narrative
US$63.50
FV
88.8% undervalued
intrinsic discount
-12.13%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
2 days ago
author updated this narrative
TechTarget
AN
AnalystHighTarget
Consensus Narrative from 3 Analysts
Digital Transformation And First-Party Data Will Ignite Secular Demand
Key Takeaways Enhanced AI integration and brand consolidation are driving higher market share, client retention, and recurring revenue while reducing exposure to economic cycles. Operational efficiencies and ecosystem integration are strengthening margins, cash flow, and the company's essential role in B2B technology markets.
View narrative
US$15.00
FV
59.3% undervalued
intrinsic discount
18.14%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
2 days ago
author updated this narrative
Carter's
AN
AnalystConsensusTarget
Consensus Narrative from 5 Analysts
Falling Birth Rates And Pricing Pressure Will Hurt Future Performance
Key Takeaways Declining birth rates and limited international growth constrain Carter's future revenue and earnings potential, keeping long-term demand and expansion prospects subdued. Intensifying competition from e-commerce and fast-fashion, plus cost pressures from tariffs and sustainability efforts, threaten Carter's profit margins and increase earnings volatility.
View narrative
US$24.60
FV
6.0% overvalued
intrinsic discount
-0.38%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
4
users have followed this narrative
4 days ago
author updated this narrative
Delek US Holdings
AN
AnalystHighTarget
Consensus Narrative from 12 Analysts
Secular Energy Demand And Renewables Will Energize US Refining
Key Takeaways Strong operational execution and efficiency initiatives position Delek for sustained margin expansion and earnings growth, potentially exceeding current expectations. Strategic investments in renewables and logistics diversify revenue streams, de-risk the business, and enhance valuation and margin resilience.
View narrative
US$30.00
FV
27.5% undervalued
intrinsic discount
0.68%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
2 days ago
author updated this narrative
Vericel
AN
AnalystConsensusTarget
Consensus Narrative from 8 Analysts
Expanding Regenerative Therapies Will Open New Market Horizons
Key Takeaways Expanding surgeon network, label extensions, and rising regenerative therapy demand are fueling market penetration, revenue growth, and long-term diversification opportunities. Operational improvements and strong payer acceptance are supporting margin expansion, increased profitability, and stable long-term financial performance.
View narrative
US$53.88
FV
32.7% undervalued
intrinsic discount
23.50%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
7
users have followed this narrative
4 days ago
author updated this narrative
Value any company in seconds
Popular companies